The interferons market is projected to grow from USD 10.5 billion in 2025 to USD 15.5 billion by 2035, at a CAGR of 3.9%. Interferon Beta will dominate with a 46.3% market share, while multiple sclerosis will lead the indication segment with a 39.8% share.